Home > Boards > US OTC > Biotechs > Sangamo Biosciences Inc. (SGMO)

“After getting slammed two months ago after rolling

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
ciciagt Member Profile
Member Level 
Followed By 20
Posts 2,229
Boards Moderated 0
Alias Born 01/02/03
160x600 placeholder
Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer Business Wire - 9/30/2019 4:15:00 PM
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire - 9/30/2019 8:30:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/26/2019 6:16:05 PM
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire - 8/30/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2019 5:11:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2019 5:05:41 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:45:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 4:38:07 PM
Sangamo Therapeutics Reports Second Quarter 2019 Financial Results Business Wire - 8/7/2019 4:01:00 PM
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire - 8/6/2019 4:05:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/6/2019 4:03:48 PM
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel Business Wire - 7/31/2019 4:15:00 PM
Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast Business Wire - 7/31/2019 4:05:00 PM
Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases Business Wire - 7/29/2019 11:00:00 AM
Sangamo et Pfizer annoncent des résultats de phase 1/2 mis à jour pour la thérapie génique expérimentale de l’hémoph... Business Wire - 7/8/2019 10:05:00 AM
Sangamo Therapeutics Up 17%; Unveiled Updated Study Data Dow Jones News - 7/8/2019 8:43:00 AM
Sangamo & Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained In... Business Wire - 7/5/2019 11:15:00 PM
 Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger P... Business Wire - 7/1/2019 11:00:00 AM
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019 PR Newswire (US) - 6/21/2019 9:16:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/18/2019 5:03:05 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:03:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:14:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:10:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:09:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:08:23 PM
ciciagt Member Level  Tuesday, 04/02/19 09:38:40 AM
Re: None
Post # of 340 
“After getting slammed two months ago after rolling out the first in vivohuman data available from a rare disease study using its gene editing tech, the players at Sangamo have earned some hard won respect on Wall Street today after posting a snapshot of promising, though very early stage, results for their hemophilia A gene therapy, partnered with Pfizer.
Focusing on the high-dose cohort — with only 2 patients getting a 3e13 vg/kg dose of SB-525 — researchers spotlighted FVIII activity of 140% and 94%, or 93% and 65% of normal, depending on which assay they used. That’s very competitive in a field dominated up to now by BioMarin $BMRN and Spark, now being acquired by Roche, so long as it holds up.

One ex vivo gene editing program also gathered some initial responses in beta thalassemia and Sangamo outlined plans to beef up its AAV manufacturing operations with a new contract signed with Brammer Bio while its own facility is under construction.

Sangamo’s shares $SGMO slowly swelled in pre-market trading as the positive message sunk in. Then it soared. Its stock was up more than 50% before the bell......”
https://www.investorvillage.com/smbd.asp?mb=1933&mn=124063&pt=msg&mid=19300692

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist